
Medpace Holdings MEDP
$ 531.0
-0.16%
Quarterly report 2025-Q2
added 07-22-2025
Medpace Holdings Gross Profit 2011-2025 | MEDP
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Medpace Holdings
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | - | - | - | 246 M | 216 M | 175 M | 172 M | 156 M | - | 124 M | - | - |
All numbers in USD currency
Indicator range from annual reports
Maximum | Minimum | Average |
---|---|---|
246 M | 124 M | 181 M |
Gross Profit of other stocks in the Diagnostics research industry
Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
---|---|---|---|---|---|---|
![]() |
Danaher Corporation
DHR
|
14.2 B | $ 204.96 | -1.82 % | $ 150 B | ![]() |
![]() |
Centogene N.V.
CNTG
|
17.2 M | $ 0.33 | -6.23 % | $ 30.6 M | ![]() |
![]() |
Fluidigm Corporation
FLDM
|
83.3 M | $ 3.75 | 1.08 % | $ 308 M | ![]() |
![]() |
Global Cord Blood Corporation
CO
|
1.06 B | $ 2.99 | - | $ 399 M | ![]() |
![]() |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | $ 21.99 | - | $ 562 M | ![]() |
![]() |
Genetron Holdings Limited
GTH
|
281 M | $ 4.03 | 0.12 % | $ 80.1 M | ![]() |
![]() |
Lantheus Holdings
LNTH
|
988 M | $ 53.55 | 3.3 % | $ 3.71 B | ![]() |
![]() |
Chembio Diagnostics
CEMI
|
6.58 M | $ 0.46 | 0.22 % | $ 16.8 M | ![]() |
![]() |
Meridian Bioscience
VIVO
|
188 M | $ 33.97 | - | $ 1.49 B | ![]() |
![]() |
HTG Molecular Diagnostics
HTGM
|
4.56 M | $ 0.48 | -20.0 % | $ 1.06 M | ![]() |
![]() |
Neogen Corporation
NEOG
|
421 M | $ 5.82 | 4.11 % | $ 1.26 B | ![]() |
![]() |
Quotient Limited
QTNT
|
23.3 M | $ 0.32 | -11.32 % | $ 1.1 M | ![]() |
![]() |
Pacific Biosciences of California
PACB
|
52.8 M | $ 1.51 | 7.86 % | $ 383 M | ![]() |
![]() |
Bioventus
BVS
|
328 M | $ 6.76 | 1.65 % | $ 423 M | ![]() |
![]() |
PRA Health Sciences, Inc.
PRAH
|
869 M | $ 165.21 | - | $ 10.7 B | ![]() |
![]() |
Heska Corporation
HSKA
|
111 M | $ 119.99 | - | $ 1.31 B | ![]() |
![]() |
Trinity Biotech plc
TRIB
|
21.4 M | $ 1.06 | -0.47 % | $ 61.9 M | ![]() |
![]() |
Twist Bioscience Corporation
TWST
|
6.96 M | $ 32.79 | 5.37 % | $ 1.9 B | ![]() |
![]() |
Motus GI Holdings
MOTS
|
-398 K | $ 0.17 | -34.28 % | $ 263 K | ![]() |
![]() |
Biocept
BIOC
|
6.12 M | $ 0.43 | -13.05 % | $ 7.29 M | ![]() |
![]() |
Syneos Health
SYNH
|
4.42 B | $ 42.98 | - | $ 4.46 B | ![]() |
![]() |
Invitae Corporation
NVTA
|
98.7 M | $ 0.09 | - | $ 21.2 M | ![]() |
![]() |
DermTech
DMTK
|
276 K | $ 0.09 | -11.32 % | $ 2.94 M | ![]() |
![]() |
Akumin
AKU
|
53.5 M | $ 0.29 | -17.87 % | $ 25.9 M | ![]() |
![]() |
Castle Biosciences
CSTL
|
53 M | $ 23.59 | 2.92 % | $ 655 M | ![]() |
![]() |
DarioHealth Corp.
DRIO
|
5.98 M | $ 16.37 | 5.27 % | $ 464 M | ![]() |
![]() |
Brainsway Ltd.
BWAY
|
30.6 M | $ 15.53 | 1.94 % | $ 99.4 M | ![]() |
![]() |
PerkinElmer
PKI
|
523 M | $ 115.24 | -0.91 % | $ 14.7 B | ![]() |
![]() |
OpGen
OPGN
|
366 K | $ 1.96 | -16.95 % | $ 1.54 M | ![]() |
![]() |
Guardant Health
GH
|
144 M | $ 65.32 | 2.96 % | $ 8.02 B | ![]() |
![]() |
DexCom
DXCM
|
2.29 B | $ 67.78 | 2.65 % | $ 26.2 B | ![]() |
![]() |
Organovo Holdings
ONVO
|
1.87 M | $ 2.12 | -2.3 % | $ 19.4 M | ![]() |
![]() |
Burning Rock Biotech Limited
BNR
|
364 M | $ 8.82 | -2.17 % | $ 94.9 M | ![]() |
![]() |
Biomerica
BMRA
|
498 K | $ 2.88 | 1.41 % | $ 6.62 M | ![]() |
![]() |
Fulgent Genetics
FLGT
|
107 M | $ 22.83 | 0.88 % | $ 690 M | ![]() |
![]() |
Psychemedics Corporation
PMD
|
8.41 M | $ 2.67 | -1.84 % | $ 15.3 M | ![]() |
![]() |
Genetic Technologies Limited
GENE
|
-251 K | $ 0.77 | - | $ 7.1 B | ![]() |
![]() |
Myriad Genetics
MYGN
|
585 M | $ 7.64 | 1.46 % | $ 692 M | ![]() |
![]() |
Renalytix AI plc
RNLX
|
156 K | $ 0.21 | 5.66 % | $ 22.7 M | ![]() |
![]() |
CareDx, Inc
CDNA
|
81.6 M | $ 14.79 | 0.82 % | $ 795 M | ![]() |
![]() |
IQVIA Holdings
IQV
|
3.79 B | $ 200.6 | -0.13 % | $ 36.4 B | ![]() |
![]() |
Koninklijke Philips N.V.
PHG
|
7.77 B | $ 28.25 | 1.51 % | $ 20 B | ![]() |
![]() |
Biodesix
BDSX
|
18.5 M | $ 7.75 | 6.16 % | $ 1 B | ![]() |
![]() |
T2 Biosystems
TTOO
|
-3.15 M | $ 0.12 | -39.35 % | $ 313 K | ![]() |
![]() |
Quidel Corporation
QDEL
|
1.35 B | $ 27.86 | 0.56 % | $ 1.17 B | ![]() |
![]() |
Agilent Technologies
A
|
2.84 B | $ 140.81 | 1.62 % | $ 42.8 B | ![]() |
![]() |
Co-Diagnostics
CODX
|
2.63 M | $ 0.39 | 5.12 % | $ 11.4 M | ![]() |